Moors & Cabot, Inc. Prothena Corp Public LTD CO Transaction History

Moors & Cabot, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 05, 2021	BUY	$48.2 - $78.89 $1.07 Million - $1.74 Million	22,119 New	22,119 $1.65 Million
Q4 2020 Feb 11, 2021	SELL	$10.12 - $13.94 $145,222 - $200,039	-14,350 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$9.93 - $13.47 $142,495 - $193,294	14,350 New	14,350 $143,000
Q1 2020 May 12, 2020	SELL	$7.54 - $15.77 $90,857 - $190,028	-12,050 Closed	0 $0
Q4 2019 Jan 28, 2020	SELL	$7.48 - $17.01 $33,286 - $75,694	-4,450 Reduced 26.97%	12,050 $190,000
Q1 2019 May 01, 2019	BUY	$10.32 - $14.49 $170,280 - $239,085	16,500 New	16,500 $198,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.